Teva Pharmaceutical Industries LTD Form 4 insider transactions

Eric A. Hughes, EVP of Global R&D and Chief Medical Officer at Teva Pharmaceutical Industries, reported the vesting of restricted share units and a subsequent sale of shares to cover tax obligations.

Teva Pharmaceutical Industries Ltd.'s Chief Financial Officer, Eliyahu Sharon Kalif, reported the vesting of previously granted restricted share units and the acquisition of new units.

Teva Pharmaceutical Industries' EVP, U.S. Commercial, Christine Fox, reported RSU vesting, a tax-related share sale, and a new RSU grant.

Teva Pharmaceutical Industries' Interim Chief Legal Officer, Brian Savage, reported the vesting of restricted share units, subsequent share acquisitions, and sales to cover tax obligations.

Amir Weiss, Teva's Chief Accounting Officer, reported the vesting of restricted share units and a new RSU grant on March 4, 2026.

Teva Pharmaceutical Industries Ltd.'s Chief Accounting Officer, Amir Weiss, acquired 5,179 ordinary shares through the vesting of restricted share units.

Richard Daniell, Teva's EVP, Europe Commercial, sold ordinary shares on March 3, 2026, following the vesting of restricted share units, including shares to cover tax obligations.

Mark Sabag, Teva Pharmaceutical Industries' Executive Vice President, International Markets Commercial, exercised restricted share units on March 3, 2026.

Teva's Interim Chief Legal Officer, Brian Savage, exercised restricted share units and sold a portion of the resulting ordinary shares to cover tax obligations.

Teva Pharmaceutical Industries CEO Richard D. Francis executed a Rule 10b5-1 plan, acquiring shares from vested restricted share units and subsequently selling a portion to cover tax obligations.

Teva Pharmaceutical Industries' CFO, Eliyahu Sharon Kalif, converted restricted share units into ordinary shares, increasing direct beneficial ownership.

Teva's EVP of Global R&D and Chief Medical Officer, Eric A. Hughes, sold shares to cover tax obligations following the vesting of restricted stock units.

Teva Pharmaceutical Industries Ltd.'s EVP and CFO, Eliyahu Sharon Kalif, was granted 141,478 restricted share units following the satisfaction of performance criteria.

Teva Pharmaceutical Industries Ltd. Executive Vice President Eric A. Hughes acquired 141,478 restricted share units, which are subject to time-based vesting until March 3, 2026.

Teva Pharmaceutical Industries Ltd. Executive Vice President Mark Sabag acquired 141,478 restricted share units, which are subject to time-based vesting until March 3, 2026.

Richard Daniell, Teva's Exec. VP, European Commercial, reported the acquisition of 141,478 restricted share units.

Teva Pharmaceutical Industries Ltd.'s President and CEO, Richard D. Francis, reported the future acquisition of over 1.5 million Restricted Share Units, vesting in early 2026.

Teva Pharmaceutical Industries Ltd.'s Chief Accounting Officer, Amir Weiss, sold 12,300 ordinary shares for approximately $30.20 per share under a pre-arranged trading plan.

Teva Pharmaceutical Industries Director Roberto Mignone sold 77,400 ordinary shares for approximately $2.3 million on December 16, 2025, under a pre-arranged 10b5-1 plan.

Teva Pharmaceutical Industries' Executive VP of European Commercial, Richard Daniell, exercised stock options and subsequently sold a significant number of ordinary shares.

Mark Sabag, Teva Pharmaceutical Industries' EVP, exercised stock options and subsequently sold over 216,000 ordinary shares for approximately $6.2 million.

Teva Pharmaceutical Industries Director Chen Lichtenstein converted 4,804 restricted share units into ordinary shares on December 2, 2025.

Roberto Mignone, a director at Teva Pharmaceutical Industries, sold 50,000 ordinary shares for approximately $26.03 per share under a pre-arranged trading plan.

Christine Fox, Teva's EVP, Head of U.S. Commercial, sold a portion of her ordinary shares to cover tax obligations following the vesting of restricted share units.

Teva’s U.S. Commercial chief sold 30,000 shares at $25.1107 and now holds 28,384 shares.

Teva Pharmaceutical Industries Director Roberto Mignone reported the sale of 200,000 ordinary shares for approximately $4.82 million.

Amir Weiss, Teva Pharmaceutical Industries' Chief Accounting Officer, sold 12,300 ordinary shares for a weighted average price of $24.4361 per share.

Teva Pharmaceutical's EVP, Chief Legal Officer, David R. McAvoy, plans to acquire 1,113 ordinary shares for approximately $21,000 in a future transaction.

Placid Jover, EVP and Chief Human Resources Officer at Teva Pharmaceutical Industries, sold 6,053 shares to cover tax obligations after restricted share units vested.

Teva Pharmaceutical Industries' Executive Vice President, Eric A. Hughes, sold 52,742 ordinary shares for $15.1575 per share following the vesting of restricted share units.